Low-molecular-weight heparin in patients with non-ST-segment elevation acute coronary syndrome: Role in the emergency department

Journal of Emergency Medicine

Volumn 19, Issue 3 SUPPL., 2000, Pages

  Goodman, Shaun G ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angina; Anticoagulants; Coronary disease; Heparin; Myocardial infarction; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NITRATE; PROTAMINE; TROPONIN T;

ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; ST SEGMENT ELEVATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

EID: 0033754671     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(00)00248-1     Document Type: Article

References (49)

1. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction
2. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study
4. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial
5. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
6. Aspirin, heparin, or both to treat acute unstable angina
7. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome
8. Reactivation of unstable angina after the discontinuation of heparin
9. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group
10. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
11. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
12. Low-molecular-weight heparins
13. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
14. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group)
15. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
16. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
17. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin
18. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects
19. Differential effects of anticoagulants on the activation of platelets ex vivo
20. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
21. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin
22. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
23. Low molecular weight heparins: A valuable tool in the treatment of acute coronary syndromes
24. Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina
25. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
26. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
27. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
28. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis
29. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
30. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group
31. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
32. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
33. Randomised trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One year results of the ESSENCE study
34. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial
35. Is the use of low-molecular-weight heparin (enoxaparin) in acute coronary syndrome patients cost saving in Canada?
36. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
37. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
38. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome)
39. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
40. The cost of unfractionated low-molecular weight heparin in the management of acute coronary syndromes
41. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
42. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
43. Low-molecular-weight heparins in coronary stenting (the ENTICES trial)
44. Safety and efficacy of percutaneous procedures in patients receiving s.c. enoxaparin for unstable angina: Results of the ESSENCE trial
45. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
46. Comparison of an intravenous bolus of enoxaparin versus unfractionated heparin in elective coronary angioplasty
47. Low molecular weight heparins in the cardiac catheterization laboratory
48. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection